• Long-term safety study of eptinezumab given by intravenous infusion for children and adolescents aged 6-17 years with chronic or episodic migraine

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy Poland Portugal Spain

  • Study on Golcadomide for Patients with Relapsed or Refractory Aggressive Large B-Cell Lymphoma at High Risk of Relapse After CAR T-Cell Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study of EXL-01 and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immunotherapy

    Recruiting

    1 1 1 1
    Investigated Drugs:
    France

  • Study on Graft-Versus-Host Disease Prevention Using Cyclophosphamide and Methotrexate in Adults with Blood Cancer Undergoing Matched-Donor Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    France

  • Study on Vagus Nerve Stimulation and Sodium Oxybate for Patients with Cerebral Amyloid Angiopathy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Austria Belgium Czechia Denmark Finland France +9

  • Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Denmark Finland Germany +8

  • Study of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis

    Recruiting

    4 1
    Investigated Drugs:
    Germany

powered by